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Abstract
Novel coronavirus disease 2019 (COVID-19) is a highly infec-
tious, rapidly spreading viral disease with an alarming case 
fatality rate up to 5%. The risk factors for severe presenta-
tions are concentrated in patients with chronic kidney dis-
ease, particularly patients with end-stage renal disease 
(ESRD) who are dialysis dependent. We report the first US 
case of a 56-year-old nondiabetic male with ESRD secondary 
to IgA nephropathy undergoing thrice-weekly maintenance 
hemodialysis for 3 years, who developed COVID-19 infec-
tion. He has hypertension controlled with angiotensin re-
ceptor blocker losartan 100 mg/day and coronary artery dis-
ease status-post stent placement. During the first 5 days of 
his febrile disease, he presented to an urgent care, 3 emer-
gency rooms, 1 cardiology clinic, and 2 dialysis centers in 
California and Utah. During this interval, he reported nau-
sea, vomiting, diarrhea, and low-grade fevers but was not 
suspected of COVID-19 infection until he developed respira-
tory symptoms and was admitted to the hospital. Imaging 
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studies upon admission were consistent with bilateral inter-
stitial pneumonia. He was placed in droplet-eye precautions 
while awaiting COVID-19 test results. Within the first 24 h, he 
deteriorated quickly and developed acute respiratory dis-
tress syndrome (ARDS), requiring intubation and increasing 
respiratory support. Losartan was withheld due to hypoten-
sion and septic shock. COVID-19 was reported positive on 
hospital day 3. He remained in critical condition being treat-
ed with hydroxychloroquine and tocilizumab in addition to 
the standard medical management for septic shock and 
ARDS. Our case is unique in its atypical initial presentation 
and highlights the importance of early testing.
© 2020 S. Karger AG, Basel
Introduction
The novel coronavirus disease (COVID-19), also 
known as COVID-19 (and SARS-Cov2) by the World 
Health Organization, is a rapidly evolving pandemic 
[1]. It is believed that this virus evolved from an un-
known species of bat at a Wuhan “wet” animal market 
in Southern China [2]. COVID-19 is estimated to have 
a case fatality rate of 2–3%, but a wide range of mortal-
ity rates between 0.2 and 8% has been reported, likely 
reflecting variable background implementation of pub-
lic health interventions [3]. The outbreak is expected to 
infect a large portion of the world population [4], and 
a case fatality rate of 1–3% represents a significant mor-
tality and healthcare burden [5]. The long-term pulmo-
nary complications in individuals who recover from 
moderate and severe COVID-19 infections remain un-
clear [6]. 
A matter of great interest is the wide spectrum of 
 COVID-19 symptomatology and disease manifestation, 
ranging from completely asymptomatic carriers [17] to 
critical respiratory failure, multiorgan dysfunction, and 
death. The severe presentations with often fatal outcomes 
have consistently been associated with several comorbid-
ities including cardiovascular disease and advanced age 
[7]. There is likely an immunologic explanation, given 
our current understanding of weakened immune system 
in diabetics and individuals with advanced age. It is not 
clear whether dialysis-dependent patients with end-stage 
renal disease (ESRD) are at greater risk for severe disease 
manifestations and poorer outcomes. We present a case 
of COVID-19 in the United States in a long-term dialy-
sis-dependent ESRD patient reported thus far in the 2020 
COVID-19 pandemic.
Case Report
Our patient is a 56-year-old male with ESRD secondary to bi-
opsy-proven IgA nephropathy on hemodialysis since late 2016. He 
has known coronary artery disease with ischemic cardiomyopathy, 
and he underwent percutaneous coronary intervention to left an-
terior descending and right coronary arteries shortly after initia-
tion of dialysis. He had an improvement in his cardiac ejection 
fraction, from 44% in 2016 to 52% on optimal medical therapy. He 
was initiated on losartan at 25 mg daily when diagnosed with isch-
emic cardiomyopathy, which was increased to the maximum toler-
ated dose of 100 mg daily about 12 months prior to this admission. 
He is a working professional, remains active, and compliant to his 
prescribed medications and treatments. Up to this point, he has 
been actively listed for a renal transplant. 
The patient had recently traveled to South Korea in early 
 January 2020 and had returned to the United States by late January 
but before the surge of COVID-19 epidemic in Daegu, South Ko-
rea, was identified. He remained in good health without any no-
table symptoms until early March 2020. 
Five days prior to his admission, he presented to a local urgent 
care for evaluation of nausea, vomiting, abdominal cramps, and 
subjective fevers; notably, he had no respiratory complaints. He 
was diagnosed with viral gastroenteritis, given recommendations 
for symptom management and discharged home. That same eve-
ning, he presented to our emergency department with similar 
complaints. He was noted to have a low-grade temperature to 
100.2°F. His laboratory tests, including electrolytes, liver function 
tests, lactic acid, and blood counts, were unremarkable. His chest 
X-ray at that time showed no significant focal consolidation, but 
mild patchy increased interstitial markings at the bilateral lung 
bases were noted and described as possible atelectasis. His nausea 
improved while in the emergency department, and his symptoms 
were again attributed to a viral gastroenteritis from some “bad 
sushi” he had reported eating a day prior. Following discharge 
from the emergency department, he went home and noted that 
he was feeling better except that he had developed some loose 
stools. 
Two days later, he attended his routine outpatient hemodialysis 
treatment, where he reported feeling better since discharge from the 
emergency department but continued to have intermittent loose 
stools approximately 2 times per day. He did not report cough or 
respiratory symptoms at that time. At the end of dialysis, he was 
noted to be febrile to 100.4°F and blood cultures were sent which 
showed no bacterial growth. He was seen in Cardiology clinic later 
that morning after dialysis treatment for an elective appointment, 
where he was noted to be coughing in the waiting room and given 
strict precautions, given his intent to travel for essential reasons. 
The following day the patient traveled by commercial airline 
from Southern California to Utah where he presented to an emer-
gency department for continued intermittent vomiting and fevers 
but was now reporting mild congestion and cough. A new chest 
X-ray at that time in Utah noted “mild interstitial prominence and 
vague infiltrate in the right lung base.” His influenza testing was 
reported negative, and he was prescribed azithromycin given the 
chest X-ray findings. The next day, he attended his scheduled he-
modialysis as a transient visitor in a community dialysis facility in 
Utah where he reported fever and malaise but was eager to return 
to California given his acute sickness. He returned to Southern 
California that evening earlier than planned using commercial air-
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line, because he was feeling quite ill with continued fevers and gas-
trointestinal symptoms. Furthermore, his respiratory symptoms, 
which were initially minimal, had progressed rapidly and he was 
becoming more short-of-breath. 
Shortly after returning to Southern California, he presented to 
our emergency department for further reevaluation. In the ED, a 
repeat chest X-ray (Fig. 1) demonstrated subtle patchy opacities in 
both lungs, new from prior X-ray 5 days ago. A CT (Fig. 1) of the 
chest revealed multifocal bilateral patchy ground glass opacities 
predominantly with peripheral distribution concerning for atypi-
cal pneumonia and possibly viral infection. COVID-19 testing was 
performed, the result of which was expected 48 h later, along with 
standard chemistry and hematology labs, which again revealed no 
abnormalities with the exception of an elevated procalcitonin lev-
el. An evaluation for other causes of atypical pneumonia was si-
multaneously sent, without additional findings thus far. 
He was admitted to the hospital on droplet – eye precautions. 
Initially, he was noted to have a temperature of 100.6°F, but with 
otherwise normal vital signs. He was initiated on antimicrobial 
therapy with ceftriaxone and azithromycin. Over the next 24 h, he 
was febrile to 101°F and respiratory status rapidly deteriorated. His 
repeat chest X-rays demonstrated evolution of the bilateral multi-
focal opacities consistent with the atypical pneumonia, and there 
was concern for superimposed pulmonary edema. He underwent 
dialysis the evening of hospital day 2; he tolerated the treatment 
poorly, developing new atrial fibrillation with rapid ventricular 
rate despite only minimal ultrafiltration. His respiratory condition 
continued to rapidly decline during the night, and he had to be 
intubated and transferred to the intensive care unit (ICU) for acute 
hypoxic respiratory failure and shock. His pulmonary condition 
continued to deteriorate to acute respiratory distress syndrome 
(ARDS) requiring continued mechanical ventilation with high 
PEEP > 10 cm and FiO2 > 60% as well as pressor support. In an ef-
fort to maintain close control of his volume status and metabolic 
parameters, we have initiated him on continuous veno-venous he-
modiafiltration. In the setting of ESRD, he has been deemed not a 
candidate for remdesivir compassionate use trial and was started 
on hydroxychloroquine and on hospital day 6 he was started on 
tocilizumab given continued hemodynamic instability with elevat-
ed inflammatory markers including interleukin (IL)-6. With the 
inability to rule out superimposed infection he has also been on 
broad-spectrum antibiotic coverage with vancomycin and piper-
acillin-tazobactom since hospital day 6. His clinical course is being 
followed closely by a multispecialist team, and depending on his 
trajectory, he may require paralysis as well as more aggressive pul-
monary and hemodynamic support with proning and extracorpo-
real membrane oxygenation. At the current time, his vasopressor 
requirement remains variable, as does his PaO2/FiO2 ratio, while 
Fig. 1. Imaging demonstrating progression of interstitial pneumo-
nitis due to COVID-19 resulting in ARDS. a Chest X-ray sequence 
with interval increasing patchy opacities in both lungs consistent 
with evolving infectious process. b Chest CT showing new multi-
focal bilateral patchy groundglass opacities with a predominantly 
peripheral distribution. There is mild bibasal septal and centri-
lobular thickening. No evidence of pleural effusion or pneumotho-
rax. There are small biapical subpleural blebs and mild centrilobu-
lar pulmonary emphysema in the upper lobes. No evidence of at-
electasis. These findings are more consistent with atypical 
pneumonia which may be secondary to viral infection. Please cor-
relate clinically. Differential considerations include pulmonary 
edema.
3/7/2020 3/12/2020
3/12/2020
3/13/2020
b
a
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he remains in critical condition for the past 5 days. Table 1 sum-
marizes timeline. Figure 1 shows chest X-ray and CT scans dem-
onstrating interstitial pneumonitis due to COVID 19.
Discussion
COVID-19 infection is a rapidly developing field, and 
we should expect more infected dialysis patients’ case re-
ports and analyses. In a recent research letter by Arentz et 
al. [8], clinical characteristics of 21 patients including 2 
long-term dialysis admitted to an ICU in Washington 
State were described. A unique feature of our reported 
case is the potentially long incubation period, assuming 
this patient contracted the infection in South Korea in ear-
ly January 2020, which was 6 weeks prior to the first pre-
sentation, but we cannot be certain. Alternatively he could 
be one of the first community spread cases identified in 
southern California. The delayed diagnosis for the first 5 
days was likely because it was not recognized by the treat-
ing centers that gastrointestinal manifestation may be a 
part of COVID-19 infection. Our reported dialysis-de-
pendent patient is notably healthier and younger than the 
average dialysis patients in the United States and without 
diabetes but with a history of hypertension and cardiac 
disease. Yet, he developed ARDS and has required ventila-
tory support. This case report highlights the importance 
of considering COVID-19 infection in a variety of clinical 
presentation that may not initially include typical respira-
tory symptom to prevent ongoing exposure of potentially 
affected individuals to the general population. It also high-
lights the need for rapidly available testing for all patients 
who present to healthcare setting with even nonsevere and 
atypical symptoms. This patient with community spread 
disease traveled from Southern California to Utah for 2 
days using public airports, commercial flights, and public 
transportation, potential exposures which could have 
been avoided if testing supplies and public health recom-
mendations would have been different. The consequences 
of this exposure remain unclear, but the United States has 
since had a rapidly increasing number of cases.
The gastrointestinal presentation our patient is some-
what unusual and delayed initiation of COVID-19 diag-
nostic workup by 5 days. Notably, however, the first case 
of COVID-19 infection confirmed in the United States re-
ported a 2-day history of nausea and vomiting on admis-
sion followed by loose stools on hospital day 2 [9], and 
COVID-19 viral nucleic acids of loose stool and respira-
tory specimens were reported positive. In a recent report 
from Hubei, China, 204 COVID-19-infected patients were 
studied, and the authors reported that digestive symptoms 
are not uncommon in patients with COVID-19 [10]. Pa-
tients who presented with gastrointestinal symptoms had 
a longer time from onset to admission, evidence of longer 
coagulation, and higher liver enzyme levels. Hence, clini-
cians including nephrologists should recognize that diges-
tive symptoms, such as diarrhea, may be among the pre-
senting features of COVID-19 infection, and that the in-
dex of suspicion may need to be raised earlier in at-risk 
patients presenting with digestive symptoms [10].
COVID-19 is a challenge to the existing health systems 
due to its novelty, rapidity of spread, asymptomatic shed-
ding, variable manifestations, and poor outcomes in mul-
timorbid or elderly persons [3]. The mortality rate is cur-
Table 1. Timeline of ESRD patient with COVID-19 presentation
Date Location Facility Symptoms
1–13 Jan 2020 South Korea N/A None 
24 Feb 2020 Southern California Dialysis center None 
4 Mar 2020 Southern California Dialysis center None
7 Mar 2020 a.m. Southern California ER 1 Nausea, vomiting, subjective fever 
7 Mar 2020 p.m. Southern California ER 2* Nausea, vomiting, fever
9 Mar 2020 a.m. Southern California Dialysis center Fever, diarrhea/loose stools
9 Mar 2020 a.m. Southern California Outpatient clinic Cough, fever
10 Mar 2020 a.m. Utah ER 3 Cough, congestion, nausea, fever
11 Mar 2020 a.m. Utah Dialysis center Cough, congestion, nausea, fever
12 Mar 2020 a.m. Southern California ER 2* inpatient Cough, congestion, SOB, fever, nausea, myalgias
13 Mar 2020 p.m. Southern California Inpatient Hypoxic respiratory failure Atrial fibrillation with RVR
14 Mar 2020 a.m. Southern California Intensive care unit ARDS; shock 
* Patients visited “ER 2” twice including upon hospital admission. 
ESRD, end-stage renal disease; COVID-19, novel coronavirus disease 2019; N/A, not applicable.
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rently estimated to be between 10 and 30 times as lethal 
as influenza, though as the incidence of the disease rises 
this may change [5]. This pandemic has resulted in a mas-
sive effort worldwide to quarantine suspected individuals 
and isolate the affected patients, unparalleled in modern 
history. The plan to “flatten the curve” is presumed only 
way our health system is expected to cope with the crisis 
by reducing demand for hospital and ICU beds [11]. 
The reason for higher incidence and mortality of CO-
VID-19 infection in individuals with several comorbidities 
including cardiovascular disease is still unknown [7]. Prior 
studies suggested that angiotensin-converting enzyme 2 
(ACE2)-binding capacity is strongly associated with coro-
navirus infectivity and disease severity. ACE2 may be dif-
ferentially upregulated by ACEi, ARB, and aldosterone an-
tagonists [12–14]. It is postulated that the expression of 
ACE2 may be increased with the use of ACEi, ARB, and 
aldosterone antagonists, particularly in diabetic patients, 
and therefore it has been suggested that increased expres-
sion of ACE2 may facilitate infection by COVID-19. It is 
important to note, however, that higher ACE2 levels have 
been shown to have a protective effect against acute lung 
injury and reduce progression of lung injury to ARDS in 
animal studies. As a result, there are ongoing investigations 
for ACE2 as potential new therapy for inflammatory lung 
disease [15]. ACE2 has been noted to decrease with age, 
and COVID-19 has consistently demonstrated higher 
mortality and morbidity in the older population. Figure 2 
shows the pathophysiological interplay between viral entry 
and lung physiology centered around ACE2. 
Currently, treatment has increasingly centered around 
3 agents including chloroquine-based agents like hy-
droxychloroquine [16]. These antimalarial agents have 
shown potent antiviral activity in vitro, especially hy-
droxychloroquine [16]. Lopinavir-ritonavir is also being 
used clinically [17]; however, whereas an emerging agent 
for COVID-19 infection is remdesivir [18], unfortunate-
ly patients with ESRD are excluded from current trials. 
Toculizumab is an antagonist of the IL-6 receptor an 
agent that has been used to treat cytokine-release syn-
drome a severe but anticipated toxicity with CAR-T-cell 
therapy in different malignancies. Similarly in severe in-
fections with hyperinflammation immunosuppression 
may improve survival, and there are preliminary reports 
from China regarding patients with elevated IL-6 levels 
and COVID-19 pneumonia. Given clinical deterioration 
in our patient and concern for hyperinflammation with 
elevated IL-6 levels, we have started tocliziumab. 
While working on treatment for severely ill patient, 
this pandemic has required and continues to require 
broad attention of public health official to implement so-
cial distancing to mitigate the rapid spread of this highly 
contagious and potentially life-threatening novel virus. 
Vaccine development is anticipated but may take time 
and if successful will help establish herd immunity to pro-
tect the noninfected population at large. 
AC
E2
An
gio
ten
sin
 I
An
gio
ten
sin
 II
AC
E 1
An
gio
ten
sin
 II
AC
E in
hib
itor
s,
Mo
st A
RBs
Ang
iote
nsin
 1–
7
AC
E in
hib
itor
s,
AR
B
Vir
al e
ntr
y 
No
 ev
ide
nce
 of
inc
rea
sed
 vir
al R
NA
In c
ells
 
Promotes anti inflammatory
Transcription to decrease
Inflammatory response
Decrease risk of ARDS
Increases
Pne
um
ocy
te
COVID
19
AC
E2Fig. 2. The complex interplay between An-
giotensin Receptor 2 and Rennin-angio-
tensin-aldosterone system blockade in 
pneumocytes. ACE, angiotensin-convert-
ing enzyme; ARB, angiotensin receptor 
blockers; ARDS, acute respiratory distress 
syndrome; COVID-19, novel coronavirus 
2019; DNA, deoxyribonucleic acid.
C
ol
or
 v
er
si
on
 a
va
ila
bl
e 
on
lin
e
Ferrey et al.Am J Nephrol6
DOI: 10.1159/000507417
As the scientific and medical community faces the un-
known surge of COVID-19, some of our most vulnerable 
populations are already gathered for routine treatments 
in limited space; for example, infusion centers and dialy-
sis centers placing them at great risk for exposure. The 
importance of rapid use of clinical publication data is par-
amount to making progress and spreading innovation. 
We have reported one of the first patients with ESRD un-
dergoing hemodialysis with COVID-19 infection. This 
scenario presents various epidemiological challenges as 
far as containing infectious spread in a dialysis unit. This 
scenario also suggests that home dialysis maybe a protec-
tive intervention in the face of such a rapidly infectious 
pandemic.
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